Table 1 Characteristics of the localized prostate cancer patients.
From: Uncovering interpretable potential confounders in electronic medical records
| Â | Treatment groups | ||
|---|---|---|---|
Features | Surgery (n = 988) | Radiation (n = 385) | Monitoring (n = 449) |
Age, mean (std) | 64.04 (7.8) | 70.18 (7.6) | 66.22 (8.2) |
Race, no. (%) | Â | Â | Â |
 White | 709 (71.8%) | 221 (57.4%) | 292 (65.0%) |
 Black | 32 (3.2%) | 15 (3.9%) | 14 (3.1%) |
 Asian | 94 (9.5%) | 41 (10.6%) | 42 (9.4%) |
 Unknown | 153 (15.4%) | 108 (28.1%) | 101 (22.5%) |
Ethnicity, no. (%) | Â | Â | Â |
 Hispanic | 71 (7.1%) | 20 (5.2%) | 23 (5.1%) |
 Non-Hispanic | 890 (90.1%) | 348 (90.4%) | 393 (87.5%) |
 Unknown | 27 (2.7%) | 17 (4.4%)) | 33 (7.3%) |
Clinical stage, no. (%) | Â | Â | Â |
 Stage I | 219 (22.2%) | 36 (9.4%) | 227 (50.6%) |
 Stage II | 750 (75.9%) | 289 (75.1%) | 217 (48.3%) |
 Stage III | 12 (1.2%) | 38 (9.9%) | 3 (0.7%) |
 Stage IV | 7 (0.7%) | 22 (5.7%) | 2 (0.4%) |
Tumor grade, no. (%) | Â | Â | Â |
 Grade 1 | 66 (66.8%) | 33 (8.6%) | 157 ((35.0%) |
 Grade 2 | 429 (43.4%) | 132 (34.3%) | 205 (45.7%) |
 Grade 3 | 474 (48.0%) | 208 (54.0%) | 62 (13.8%) |
 Grade 4 | 3 (0.3%) | 2 (0.5%) | 0 (0%) |
 Unknown | 16 (1.6%) | 10 (2.6%) | 25 (5.6%) |
No. notes/patient, mean (std) | 24.96 (44.4) | 53.93 (105.7) | 54.48 (93.4) |
Days of survival, mean (std) | 1564.90 (979.4) | 1424.76 (1,031.6) | 1403.72 (921.2) |
Death, no. (%) | 70 (7.1%) | 19 (4.9%) | 17 (3.8%) |
